Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ocugen Inc (OCGN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME6500FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ocugen Inc (Ocugen), formerly Histogenics Corp, is a biopharmaceutical company that discovers, develops and commercializes transformative drugs for the treatment of eye diseases. The company’s lead product candidate, OCU300, is a small molecule therapeutic intended for the treatment of ocular graft versus host disease (oGVHD). Ocugen develops its product candidates based on its proprietary OcuNanoE nanoemulsion technology. Its other pipeline products include OCU400, a novel gene therapy product candidate used to restore retinal integrity and function in multiple inherited retinal diseases; and OCU410, a modifier gene therapy product candidate intended to treat dry age-related macular degeneration; and OCU200, a biologic product candidate used to treat patients with diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. Ocugen is headquartered in Malvern, Pennsylvania, the US.

Ocugen Inc Key Recent Developments

Mar 18,2021: Ocugen Provides Business Update and Full Year 2020 Financial Results
Mar 12,2021: Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update
Feb 10,2021: Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
Feb 07,2021: Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market
Feb 02,2021: Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market

This comprehensive SWOT profile of Ocugen Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Ocugen Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Ocugen Inc – Key Information
Ocugen Inc – Overview
Ocugen Inc – Key Employees
Ocugen Inc – Key Employee Biographies
Ocugen Inc – Key Operational Heads
Ocugen Inc – Major Products and Services
Ocugen Inc – History
Ocugen Inc – Company Statement
Ocugen Inc – Locations And Subsidiaries
Ocugen Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Ocugen Inc – Business Description
Ocugen Inc – Corporate Strategy
Ocugen Inc – SWOT Analysis
SWOT Analysis – Overview
Ocugen Inc – Strengths
Ocugen Inc – Weaknesses
Ocugen Inc – Opportunities
Ocugen Inc – Threats
Ocugen Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Ocugen Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Ocugen Inc, Key Information
Ocugen Inc, Key Ratios
Ocugen Inc, Share Data
Ocugen Inc, Major Products and Services
Ocugen Inc, History
Ocugen Inc, Key Employees
Ocugen Inc, Key Employee Biographies
Ocugen Inc, Key Operational Heads
Ocugen Inc, Other Locations
Ocugen Inc, Subsidiaries
Ocugen Inc, Key Competitors
Ocugen Inc, SWOT Analysis
Ocugen Inc, Ratios based on current share price
Ocugen Inc, Annual Ratios
Ocugen Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ocugen Inc (OCGN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Starbreeze AB (STAR B):企業の財務・戦略的SWOT分析
    Summary Starbreeze AB (Starbreeze) is a game development company that creates, publishes and distributes entertainment products and games. The company’s published games include the outforce, enclave, knights of the temple, syndicate, the chronicles of riddick, knights of the temple, enclave, escapes …
  • Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …
  • The Shanghai Commercial & Savings Bank Ltd:企業の戦略・SWOT・財務情報
    The Shanghai Commercial & Savings Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Shanghai Commercial & Savings Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • HDFC Bank Ltd:企業の戦略・SWOT・財務情報
    HDFC Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary HDFC Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Taneja Aerospace & Aviation Ltd.:企業の戦略・SWOT・財務分析
    Taneja Aerospace & Aviation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taneja Aerospace & Aviation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Milliken & Co:企業の戦略的SWOT分析
    Milliken & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Ceapro Inc (CZO):製薬・医療:M&Aディール及び事業提携情報
    Summary Ceapro Inc (Ceapro) is a biotechnology company which develops proprietary extraction technologies for use in the production of extracts and active ingredients from oats and other renewable plant resources. The company’s extracts are also used in nutraceutical, cosmeceutical, and therapeutics …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Weizmann Institute of Science:製薬・医療:M&Aディール及び事業提携情報
    Summary Weizmann Institute of Science (WIS) is a research institute that offers research activities in the field of natural and exact sciences. The institute provides programs that include graduate programs, post graduate programs, scientific research, academic affairs, science education, research a …
  • Cavco Industries Inc:企業の戦略・SWOT・財務情報
    Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Stemline Therapeutics Inc (STML):製薬・医療:M&Aディール及び事業提携情報
    Summary Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pi …
  • GN Hearing AS-医療機器分野:企業M&A・提携分析
    Summary GN Hearing A/S (GN Hearing) formerly, GN ReSound A/S, a subsidiary of GN Store Nord A/S is a medical equipment company that provides advanced hearing health care solutions. It manufactures advanced technology hearing instruments and solutions for all types of ear-related problems. The compan …
  • Bactiguard Holding AB (BACTI B):医療機器:M&Aディール及び事業提携情報
    Summary Bactiguard Holding AB (Bactiguard) is a medical device manufacturer which develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. …
  • ProSiebenSat.1 Media SE (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media SE (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Compal Electronics, Inc.:戦略・SWOT・企業財務分析
    Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務分析
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Kukje Pharmaceutical Industry Co Ltd (002720):企業の財務・戦略的SWOT分析
    Summary Kukje Pharmaceutical Industry Co Ltd (Kukje) is a manufacturer, and distributor of pharmaceuticals, cosmetics and healthcare products. The company’s products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, other antibiotics, antifungal and antiviral agents. Kukj …
  • HD Biosciences (China) Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary HD Biosciences (China) Co Ltd (HDB), a subsidiary of WuXi AppTec (Shanghai) Co Ltd, is a contract research organization that offers drug discovery research services. The organization develops and provides products such as mycoplasma detection kit and wash free calcium assay kit, among others …
  • Ipsen SA (IPN):製薬・医療:M&Aディール及び事業提携情報
    Summary Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products …
  • Analog Devices, Inc.:戦略・SWOT・企業財務分析
    Analog Devices, Inc. - Strategy, SWOT and Corporate Finance Report Summary Analog Devices, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆